Angela Gomez-Simmonds, MD

Board Certifications: 
Infectious Disease, Internal Medicine
Accepting New Patients

Overview

Areas of Expertise / Conditions Treated

Infectious Disease

Academic Appointments

  • Instructor in Medicine at CUMC

Dr. Gomez-Simmonds’ research interests entail understanding the clinical and molecular epidemiology of hospital-associated pathogens, particularly multidrug-resistant Gram-negative bacteria. She is currently working in Dr. Anne-Catrin Uhlemann’s laboratory, where she has been focused on developing next-generation sequencing-based methods for investigating the repertoire of resistance gene and associated mobile genetic elements in these pathogens, with the goal of better understanding hospital-associated transmission of multidrug resistance. Other active areas of research include investigating the clinical, pathogen, and microbiome factors associated with colonization and subsequent infection with multidrug-resistant Gram-negative and other hospital-associated infections, such as Clostridioides difficile.

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Languages

  • Spanish

Gender

  • Female

Schedule an Appointment

Phone Appointments

New and Existing Patients:
212-305-8039

Location(s)

CUMC/Harkness Pavilion
180 Fort Washington Avenue
New York, NY 10032
Primary

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • NYP Employee Plan
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Access (Exchange)
  • EPO
  • Gatekeeper (Exchange)
  • HMO
  • Medicare Managed Care
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • MD, University of Medicine and Dentistry of New Jersey
  • Internship: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Board Certifications

  • Infectious Disease
  • Internal Medicine

Research

Dr. Gomez-Simmonds’ research interests entail understanding the clinical and molecular epidemiology of hospital-associated pathogens, particularly multidrug-resistant Gram-negative bacteria. She is currently working in Dr. Anne-Catrin Uhlemann’s laboratory, where she has been focused on developing next-generation sequencing-based methods for investigating the repertoire of resistance gene and associated mobile genetic elements in these pathogens, with the goal of better understanding hospital-associated transmission of multidrug resistance. Other active areas of research include investigating the clinical, pathogen, and microbiome factors associated with colonization and subsequent infection with multidrug-resistant Gram-negative and other hospital-associated infections, such as Clostridioides difficile.

Grants

ELUCIDATING TRANSMISSION OF PLASMIDS HARBORING BLAKPC AMONG CARBAPENEMRESISTANT ENTEROBACTERIACEAE USING LONG-RANGE SEQUENCING (Federal Gov)

Dec 1 2018 - Nov 30 2022

INSTITUTIONAL CAREER DEVELOPMENT CORE (Federal Gov)

Jul 1 2016 - May 31 2021

CARBAPENEM-RESISTANT BACTERIAL COLONIZATION AND INFECTION IN LIVER TRANSPLANT (Federal Gov)

Jan 14 2015 - Dec 31 2019

COLUMBIA INTEGRATED TRAINING PROGRAM IN INFECTIOUS DISEASE RESEARCH (Federal Gov)

Jun 1 2013 - May 31 2018

Selected Publications

Annavajhala MK, Gomez-Simmonds A, Uhlemann AC. Multidrug-resistant Enterobacter cloacae complex emerging as a global, diversifying threat. Frontiers in Microbiology 2019;10:44.

Gomez-Simmonds A, Stump S, Giddins MJ, Annavajhala MK, Uhlemann AC. Clonal background, resistance gene profile, and porin gene mutations modulate in vitro susceptibility to imipenem-relebactam in diverse Enterobacteriaceae. Antimicrobial Agents and Chemotherapy 2018;628:e00573-18.

Gomez-Simmonds A*, Annavajhala MK*, Wang Z*, Macesic N, Hu Y, Giddins MJ, O'Malley A, Toussaint NC, Whittier S, Torres VJ, Uhlemann AC. Genomic and geographic context for the evolution of high-risk carbapenem-resistant Enterobacter cloacae complex clones ST171 and ST78. MBio 2018;93:e00542-18. (*Shared first authorship)

Macesic N, Gomez-Simmonds A, Sullivan SB, Giddins MJ, Ferguson SA, Korakavi G, Leeds D, Park S, Shim K, Sowash MG, Hofbauer M, Finkel R, Hu Y, West J, Toussaint NC, Greendyke WG, Miko BA, Pereira MR, Whittier S, Verna EC, Uhlemann AC. Genomic surveillance reveals diversity of multidrug-resistant organism colonization and infection: a prospective cohort study in liver transplant recipients. Clinical Infectious Diseases 2018.

McConville TH, Sullivan SB, Gomez-Simmonds A, Whittier S, Uhlemann AC. Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study. PLoS One 2017;2:e0186195.

Gomez-Simmonds A, Uhlemann AC. Clinical implications of genomic adaptation and evolution of carbapenem-resistant Klebsiella pneumoniae. Journal of Infectious Diseases 2017;215:S18-S27.

Gomez-Simmonds A, Hu Y, Sullivan SB, Wang Z, Whittier S, Uhlemann AC. Evidence from a New York City hospital of rising incidence of genetically diverse carbapenem-resistant Enterobacter cloacae and dominance of ST171, 2007-14. Journal of Antimicrobial Chemotherapy 2016;71:2351-3.

Gomez-Simmonds A, Nelson B, Eiras D, Loo A, Jenkins SG, Whittier S, Calfee DP, Satlin M, Kubin CJ, Furuya EY. Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Antimicrobial Agents and Chemotherapy 2016;60:3601-7.

Nelson BC, Eiras DP, Gomez-Simmonds A, Loo AS, Satlin MJ, Jenkins SG, Whittier S, Calfee DP, Furuya EY, Kubin CJ. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. Antimicrobial Agents and Chemotherapy 2015;59:7000-6.

Gomez-Simmonds A, Greenman M, Sowash M, Sullivan SB, Tanner J, Uhlemann AC. Population structure of Klebsiella pneumoniae causing bloodstream infections at a New York City tertiary care hospital: diversification of multidrug-resistant isolates. Journal of Clinical Microbiology 2015;53:2060-7.

Gomez-Simmonds A, Kubin CJ, Furuya EY. Comparison of 3 severity criteria for Clostridium difficile infection. Infection Control Hospital Epidemiology 2014;35:196-9.